We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-10.66%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$551M
AUM Growth
–
Cap. Flow
+$550M
Cap. Flow %
99.74%
Top 10 Hldgs %
31.05%
Holding
130
New
130
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$21.7M
2
GILD icon
Gilead Sciences
GILD
+$21M
3
MDT icon
Medtronic
MDT
+$20.8M
4
BIIB icon
Biogen
BIIB
+$20.2M
5
AMGN icon
Amgen
AMGN
+$15.3M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 93%
2 Financials 1.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIB icon
101
ProShares Ultra NASDAQ Biotechnology
BIB
$84.1M
$736K 0.13%
+18,000
New +$796K
EXEL icon
102
Exelixis
EXEL
$14.1B
$680K 0.12%
+170,000
New +$720K
ESPR
103
DELISTED
Esperion Therapeutics
ESPR
$676K 0.12%
+40,000
New +$643K
IBB icon
104
iShares Biotechnology ETF
IBB
$9.23B
$652K 0.12%
+7,500
New +$671K
KITE
105
DELISTED
Kite Pharma, Inc.
KITE
$643K 0.12%
+14,000
New +$678K
RARE icon
106
Ultragenyx Pharmaceutical
RARE
$2.88B
$633K 0.11%
+10,000
New +$654K
TMH
107
DELISTED
Team Health Holdings Inc
TMH
$627K 0.11%
+15,000
New +$613K
CLDX icon
108
Celldex Therapeutics
CLDX
$2.77B
$605K 0.11%
+10,667
New +$1.2M
LABU icon
109
Direxion Daily S&P Biotech Bull 3X ETF
LABU
$617M
$553K 0.1%
+1,009
New +$638K
MYGN icon
110
Myriad Genetics
MYGN
$584M
$524K 0.1%
+14,000
New +$528K
ABUS icon
111
Arbutus Biopharma
ABUS
$901M
$516K 0.09%
+125,000
New +$447K
PODD icon
112
Insulet
PODD
$11.4B
$497K 0.09%
+15,000
New +$471K
RMD icon
113
ResMed
RMD
$28.9B
$463K 0.08%
+8,000
New +$453K
NVRO
114
DELISTED
NEVRO CORP.
NVRO
$422K 0.08%
+7,500
New +$442K
PEN icon
115
Penumbra
PEN
$12.5B
$368K 0.07%
+8,000
New +$374K
JNP
116
DELISTED
Juniper Pharmaceuticals, Inc. Common Stock
JNP
$331K 0.06%
+50,000
New +$368K
ECYT
117
DELISTED
Endocyte, Inc. Common Stock
ECYT
$310K 0.06%
+100,000
New +$326K
THC icon
118
Tenet Healthcare
THC
$16.8B
$289K 0.05%
+10,000
New +$260K
IMGN
119
DELISTED
Immunogen Inc
IMGN
$256K 0.05%
+30,000
New +$254K
PTCT icon
120
PTC Therapeutics
PTCT
$6.52B
$225K 0.04%
+35,000
New +$607K
TBPH icon
121
Theravance Biopharma
TBPH
$877M
$215K 0.04%
+11,248
New +$184K
XOMA
122
DELISTED
Xoma
XOMA
$174K 0.03%
+11,250
New +$203K
HTWR
123
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$157K 0.03%
+5,000
New +$169K
LRMR icon
124
Larimar Therapeutics
LRMR
$384M
$134K 0.02%
+1,667
New +$132K
SGRY icon
125
Surgery Partners
SGRY
$2.09B
$133K 0.02%
+10,000
New +$155K
2 3 4
5
6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2016 Portfolio in Review

Q1 2016 is the first quarter with a 13F filing on record for Bellevue Group, which disclosed 130 positions worth $551M. Its ten largest holdings account for 31% of the portfolio.

Its largest position is Celgene Corp: 210,550 shares worth $21.1M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, followed by Financials.

  • Bellevue Group's largest Q1 2016 buy was Celgene Corp: 210,550 shares worth $21.1M.
  • Bellevue Group's ten largest holdings make up 31% of its $551M portfolio in Q1 2016.
  • Bellevue Group disclosed 130 positions in Q1 2016, its first 13F filing on record.

Based on Bellevue Group's 13F filing for Q1 2016, filed 16 May 2016.